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enhanced formation of advanced glycation end products (AGE), dysfunction of the mitochondrial electron transport chain, and activation of the plasma membrane NADPH oxidase (3, 7) . Among these possibilities, recent attention has been focused on NADPH oxidase as a potential source of ROS production in diabetic/hyperglycemic conditions (20, 29) . This enzyme, which has been found primarily in phagocytic cells (1) , was recently shown to exist in nonphagocytic cells, such as endothelial cells, vascular smooth muscle cells, fibroblasts, and adipocytes (21, 23, 28, 31) . The phagocytic NADPH oxidase is a multicomponent enzyme, consisting of cytosolic components p47 phox , p67 phox , and the small G protein rac, as well as plasma membrane oxidase subunits (reviewed in Ref. 1) . Assembly of the enzyme's components in the membrane is required for its activation (1) . Current evidence suggests that protein kinase C (PKC) may regulate the activation of NADPH oxidase (4, 18, 20, 29) . PKCs are a family of serine/theronine protein kinases that are classified into conventional PKC (cPKC-␣, -␤, and -␥), which are calcium and diacylglycerol (DAG) dependent; novel PKC (nPKC-␦, -⑀, -, and -), which are DAG dependent but calcium independent; and atypical PKC (aPKC), which are insensitive to both calcium and DAG (34, 37) . PKC has been implicated initially in NADPH oxidase-dependent activation of several responses in phagocytic cells, because PMA triggered the production of superoxides (1) . Recent studies have implicated PKC in activation of NADPH oxidase and suggested that PKC may phosphorylate the cellular subunit p47 phox that may induce its membranous translocation (4, 15, 38, 39, 46) . PKC-␤ was shown to increase NADPH oxidase activity in diabetic glumeruli (24) , neutrophils (12) , and HL60 cells (26) . Other studies have implicated PKC-␦ as another regulator of the oxidase (2) and reported PKC-␦'s requirement for complex assembly of the enzyme's components (6) . Still, the role of PKC in the activation of NDPH oxidase in nonphagocytic cells has not been well established.
In recent years, it became evident that fat tissue has important and integral roles in the development of insulin resistance and type 2 diabetes (22, 43) . However, little is known about the mechanisms governing endogenous oxidative stress in the fat tissue, particularly those related to diabetes. In previous studies, we showed that oxidative stress is increased in adipocytes isolated from obese, insulin-resistant C57BL/6J mice (45) [an inbred mice strain susceptible to diet-induced obesity and diabetes (44) ] and demonstrated that PKC-␦ activity significantly increased in these cells compared with "normal" adipo-cytes (45) . In the present study, we hypothesized that PKC-␦ contributes to the rise in ROS production seen in high-fat diet-induced obese and insulin-resistant mouse (HF) adipocytes and examined their cellular source. Here, we show that PKC-␦ is an important player affecting cellular ROS production in both normal and diabetic adipocytes and suggest that this process is mediated by high glucose and NADPH oxidase.
MATERIALS AND METHODS
Materials. PKC-␦ antibodies (Sc-213) were from Santa Cruz Biotechnology (Santa Cruz, CA), PKC inhibitors Rottlerin and GÖ -6976 were purchased from Calbiochem (San Diego, CA), and LY-333531 was from Biomole (Plymouth Meeting, PA). Diphenyleneiodonium chloride (DPI), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), rotenone, allopurinol, N -nitro-L-arginine methyl ester hydrochloride (L-NAME), aminoguanidine, and 2Ј,7Ј-dichlorodihydrofluorescein (DCHF) were from Sigma (Rehovot, Israel).
Animal and diets. Four-week-old mice were randomly assigned to receive either standard laboratory food or a high-fat diet containing 35% lard (Bioserve, Frenchtown, NJ), in which 55% of the calories came from fat. The animals were housed in individual cages with free access to water in a temperature-controlled facility with a 12:12-h light-dark cycle; the animals were weighed periodically. Animals were used for testing after 16 wk on their designated diets. Animals were starved for 3 h before experiments and then killed. Animal care was followed according to the Tel Aviv University Institutional Animal Care and Use Committee.
Preparation of adipocytes. Adipocytes were isolated from the epididymal fat pad by digestion with 0.4 mg/ml collagenase (Worthington Biochemical, Freehold, NJ), as described previously (30, 45) . Digested fat pads were passed through nylon mesh, and the cells were washed three times with Krebs-bicarbonate buffer (pH 7.4) containing 1% bovine serum albumin (BSA, fraction V; Boehringer Mannheim, Mannheim, Germany), 10 mM HEPES (pH 7.3), 5 mM glucose, and 200 nM adenosine. Cells were centrifuged and collected from the top layer. This process enables isolation of adipocytes from other cells, such as macrophages, that were recently shown to accumulate in adipose tissue of HF mice (47) . Aliquots of cells were used to determine the cell concentrations, as described by Talior et al. (45) .
Measurement of intracellular ROS generation. The determination of ROS was based on the oxidation of the nonfluorescent DCHF into a fluorescent dye, 2Ј,7Ј-dichlorofluorescein (DCF), by peroxide as previously described, with some modifications (45) . In brief, adipocytes (10 6 ) were incubated with indicated reagents for 1 h followed by the addition of DCHF (30 M) for an additional 40 min. Cells were washed, and the fluorescence was measured in triplicate samples, using a multiplate fluorometer (Fl-600, excitation at 488 nm and emission at 530 nm). Known concentrations of DCHF incubated with 20 mM NaOH were used as standards.
Tissue infections and tissue extraction. The recombinant adenovirus vectors were constructed and used as previously described (42) . Epidydimal fat tissues were removed from control or HF animals and incubated with the PKC-␦ recombinant adenoviruses or with a "control" virus encoding ␤-galactosidase (␤-Gal) together with lipofectamine (10 g/ml; Invitrogen Life Technologies Carlsbad, CA) in Dulbecco's Modified Eagle's Medium (DMEM), with low glucose (5 mM glucose), supplemented with 1% BSA for 18 h at 37°C. The tissues were then washed with Krebs-bicarbonate buffer, and adipocytes were isolated from the infected tissues as described in the previous section. Infection efficiency was monitored by X-Gal staining (of ␤-Gal-infected tissues), which showed an efficiency of Ͼ50% of cells. Tissues were homogenized with ice-cold buffer G (25 g/ml each of 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM ␤-glycerphosphate, 50 mM NaF, 5% glycerol, 1% Triton X-100, leupeptin, aprotinin, and pepstatin A). Homogenates were centrifuged at 10,000 g, and supernatants were collected. PKC-␦ was immunoprecipitated from the supernatants with specific anti-PKC-␦ antibody subjected to gel electrophoresis and immunoblot analysis with indicated antibodies. In other sets of experiments, adipocytes were isolated from infected tissues, as described in the previous section, and incubated with indicated concentrations of glucose. ROS were measured as described earlier.
In vitro kinase activity. PKC-␦ activity was assayed as previously described (45) . In brief, adipocytes were lysed with buffer H (25 g/ml each of 20 mM Tris, pH 7.5, 50 mM ␤-glycerophosphate, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 10 mM NaF, 5% glycerol, 1% Triton X-100, leupeptin, aprotinin, and pepstatin A). The lysates were centrifuged, and equal protein aliquots were used for PKC-␦ assays. The enzyme was immunoprecipitated for 2 h with anti-PKC-␦ antibody bound to protein A-Sepharose. The immunocomplexes were washed extensively, and the kinase reaction was performed at 30°C in 20 mM Tris ⅐ HCl, pH 7.3, with 10 mM MgCl 2, 100 M [␥-32 P]ATP, Fig. 1 . Effect of diphenyleneiodonium chloride (DPI) on reactive oxygen species (ROS) levels in control and high-fat diet-induced obese and insulinresistant mouse (HF) adipocytes. A: HF or control adipocytes were incubated with indicated concentrations of DPI for 1 h, followed by addition of 2Ј,7Ј-dichlorodihydrofluorescein (DCHF) for another 40 min. Fluorescence of 2Ј,7Ј-dichlorofluorescein (DCF) was measured in a triplicate sample, as described in MATERIALS AND METHODS. Results represent means Ϯ SE of 5 independent experiments, presented as fold inhibition of ROS levels determined in control adipocytes. B: HF adipocytes were treated with allopurinol (100 M), N -nitro-L-arginine methyl ester (L-NAME, 1 mM), aminoguanidine (AMG, 10 M), and FCCP (10 M) for 1 h before addition of DCHF. Fluorescence of DCF was measured in triplicate, as described in MATERIALS AND METHODS. Results represent means Ϯ SE of 3 independent experiments, presented as fold inhibition of ROS levels determined in untreated HF adipocytes. *P Ͻ 0.05 treatment with DPI vs. no treatment.
phosphatidylserine (PS, 40 M), and 3 g of histone H1 (per reaction). Reactions were terminated after 20 min by the addition of SDS-PAGE load buffer and were analyzed in 15% SDS-PAGE. In some experiments, Rottlerin was added to the immunoprecipitates to measure Rottlerin's inhibitory properties toward PKC-␦.
Graphics and statistical analyses were performed by Origin 6.0 Professional software. A difference was considered to be statistically significant when P Ͻ 0.05. Quantitation of gel bands was performed by densitometry analysis.
RESULTS
To determine the source of intracellular ROS production, HF and control adipocytes (i.e., isolated from diabetic or healthy animals) were incubated with increasing concentrations of the NADPH oxidase inhibitor DPI (31) . The results presented in Fig. 1A indicated that DPI decreased ROS levels in both control and HF adipocytes (by ϳ50%). Notably, ROS levels were higher in HF adipocytes compared with control adipocytes. Nevertheless, treatment with DPI reduced ROS levels to the "normal" levels seen in control adipocytes (Fig. 1A) . In contrast, inhibition of other flavoproteins that may be sensitive to DPI, such as xanthine oxidase or nitric oxide synthase (NOS), with allupurinol (10 -100 M) or L-NAME (0.1-1 mM), respectively, had no effect on ROS levels (Fig. 1B) . Finally, inhibition of AGE formation by aminoguanidine [10 M (35) ] or treatment with the mitochondrial uncoupler FCCP had no effect on ROS levels in HF adipocytes (Fig. 1B) . Taken together, these results suggest that increased ROS production in HF adipocytes most likely originates from NADPH oxidase.
We next examined whether PKC-␦ might affect ROS production. HF adipocytes were incubated with the selective PKC-␦ inhibitor Rottlerin (17) 1 h before incubation with DCFH. Indeed, increasing concentrations of Rottlerin decreased ROS levels by ϳ50% (10 M Rottlerin; Fig. 2A) . Similar results were obtained with control adipocytes treated with Rottlerin. Interestingly, Rottlerin suppressed ROS to a greater extent in control cells than in HF adipocytes (68 Ϯ 17 and 48 Ϯ 6.5% control vs. HF at 10 M Rottlerin; Fig. 2A ).
There is a debate about the ability of Rottlerin to inhibit PKC-␦ (10, 16, 17) ; therefore, we examined its in vitro effect on adipocyte PKC-␦. The enzyme was immunoprecipitated from lysates prepared from HF adipocytes, and PKC-␦ activity was assayed in the immunoprecipitate complex with increasing concentrations of Rottlerin. The ability of PKC-␦ to phosphorylate the substrate histone H1 was significantly reduced by 5 and 10 M Rottlerin (Fig. 2B, top) , indicating that Rottlerin can inhibit PKC-␦ in vitro. To further confirm the specificity of the assay, we show that the kinase activity was dependent on the PKC lipid activator PS (Fig. 2B, middle) . In addition, the assays were performed in protein A beads to show that the phopshorylated signal is above background (Fig. 2B, bottom) . These studies suggested that PKC-␦ is involved in ROS production, and additional studies strengthen this point (Fig. 3) .
We further examined whether other PKC isoforms affect ROS in HF adipocytes. Treatment with GÖ -6976, an effective inhibitor toward classical PKC isoforms [i.e., ␣, ␤, ␥ (11)], or the selective PKC-␤ inhibitor LY-333531 slightly reduced Fig. 2 . Effect of PKC inhibitors on ROS levels in HF adipocytes. A: HF or control adipocytes were incubated with indicated concentrations of Rottlerin for 1 h, followed by addition of DCHF for another 40 min. Fluorescence of DCF was measured in triplicate, as described in MATERI-ALS AND METHODS. Results represent means Ϯ SE of 3 independent experiments, presented as fold inhibition of ROS levels of untreated adipocytes. B: PKC-␦ was immunoprecipitated from cell extracts prepared from HF adipocytes. In vitro PKC-␦ activity was assayed in the presence of indicated concentrations of Rottlerin, as described in MATERIALS AND METHODS. Shown is phosphorylation of histone H1 (top). To asses specificity of assays, PKC-␦ immunoprecipitates were incubated with or without phosphatidylserine (PS; middle). To show that the phosphorylated signal is above background, assays were performed on protein A-Sepharose beads only. Presence of PKC-␦ antibody is indicated. C: HF adipocytes were incubated with Rottlerin (5 M), GÖ -6976 (5 M), or LY-333531 (10 M) for 1 h, followed by addition of DCHF for another 40 min. Fluorescence of DCF was measured in triplicate, as described in MATERIALS AND METHODS, and presented as arbitrary units. Results represent means Ϯ SE of 3 independent experiments, presented as fold inhibition of ROS levels determined in untreated adipocytes. *P Ͻ 0.05. D: same as C, except that HF adipocytes were incubated with a combination of Rottlerin and DPI, as indicated. Results represent means Ϯ SE of 3 independent experiments, presented as fold inhibition of ROS levels determined in untreated adipocytes.
ROS levels (10 Ϯ 1.5 and 22 Ϯ 1.2%, respectively; Fig. 2C ). These results suggested that conventional PKC isoforms are probably not involved in ROS production. They do not exclude, however, the possibility that novel or atypical PKC isoforms are involved. We next examined the effect of a combination treatment of Rottlerin with DPI on ROS levels. Apparently, administration of both Rottlerin and DPI into HF adipocytes or control adipocytes did not further enhance the reduction in ROS levels achieved by each reagent added separately (Fig. 2D) . These results suggested that Rottlerin and DPI affect ROS via a common intracellular target, most likely NADPH oxidase.
To further assess the role of PKC-␦ in ROS production, PKC-␦ proteins were overexpressed in control and HF adipocytes by use of adenovirus-mediated gene delivery. An adenoviral vector encoding ␤-Gal was used as a control. Infection protocols were developed and optimized. Tissues infected with ␤-Gal construct were processed for X-Gal staining, and blue staining of the tissue shown in Fig. 3A confirmed the expression of ␤-Gal. In addition, adipocytes were isolated from ␤-Gal-infected tissues and processed for X-Gal staining as well. Blue staining of adipocytes confirmed the expression of ␤-Gal in adipocytes (ϳ30% efficiency; Fig. 3B ). Fat tissues were infected with either the recombinant adenovirus encoding wild-type (WT) PKC-␦ (WT-PKC-␦) or its kinase dead (DN) mutant, DN-PKC-␦. The degree of expression of PKC-␦ protein above endogenous levels was determined by Western blot analysis (Fig. 3C) . Densitometry analysis of PKC-␦ bands indicated that overexpression of WT-PKC-␦ or DN-PKC-␦ was 5 Ϯ 1.6-fold and 3 Ϯ 1-fold, respectively, above endogenous PKC-␦ of ␤-Gal-infected adipocytes. ROS levels were determined in control or HF adipocytes that expressed the PKC-␦ proteins. Overexpression of WT-PKC-␦ resulted in a twofold increase in ROS levels in both control and HF adipocytes, compared with the ␤-Gal-infected cells (Fig. 3D) . In contrast, expression of DN-PKC-␦ suppressed ROS levels by 28 Ϯ 1.9 or 20 Ϯ 1.5% in control or HF adipocytes, respectively (Fig.  3D) . These results suggest that PKC-␦ contributes to ROS production in both normal and diabetic adipocytes. Notably, the effect of DN-PKC-␦ on ROS suppression was greater in control cells than in HF adipocytes. This was because PKC-␦ activity is higher in HF adipocytes (45) , therefore "less" affected by inhibition.
We next examined whether ROS and PKC-␦ are regulated by glucose. This question was of particular importance because glucose uptake is dramatically increased in HF adipocytes (45) . Incubation of HF adipocytes with decreased glucose concentrations gradually decreased ROS levels (Fig. 4A) . Similarly, increased PKC-␦ activity correlated with increased glucose concentrations (Fig. 4B) . Moreover, suppression of ROS in reduced glucose concentrations was stronger in DN-PKC-␦-overexpressing cells than in control ␤-Gal-expressing cells (Fig. 4C) . These results suggested a functional link between glucose, PKC-␦ activity and ROS production. Fig. 3 . Overexpression of PCK-␦ proteins alters ROS levels in control and HF adipocytes. A: fat tissue was infected with ␤-galactosidase (␤-Gal) adenovirus. Infected and noninfected tissues were subjected to X-Gal staining, as described in MATERIALS AND METHODS. Blue staining of infected tissue confirms expression of ␤-Gal protein. B: adipocytes were isolated from ␤-Gal-infected fat tissue and subjected to X-Gal staining, as described in MATE-RIALS AND METHODS. Blue-stained adipocytes are shown and confirm expression of ␤-Gal protein in adipocytes. Average value of transfection efficiency obtained from 4 independent experiments was 30 Ϯ 12%. C: fat tissues were infected with wild-type (WT-) or dominant negative (DN-)PKC-␦ adenoviruses or with control ␤-Gal adenovirus, as described in MATERIALS AND METH-ODS. Tissues were homogenized in buffer G, and PKC-␦ was immunoprecipitated with specific antibodies from tissue homogenates. Immunoprecipitates were subjected to Western blot analysis with PKC-␦ antibody. D: PKC-␦ proteins expressed in infected tissues are shown. ROS levels were determined in control or HF adipocytes isolated from PKC-␦-or ␤-Gal-infected tissues. Shown is fluorescence of DCF measured in triplicate and presented as fold activation/inhibition of ROS levels determined in ␤-Gal-infected cells. Results represent means Ϯ SE of 3 independent experiments, presented as arbitrary units. *P Ͻ 0.05, PKC-␦-infected adipocytes vs. ␤-Gal-infected adipocytes.
DISCUSSION
The present study demonstrates the novel findings that PKC-␦ enhances oxidative stress in insulin-resistant adipocytes and provides evidence that this process is most likely mediated by NADPH oxidase. This oxidase, which has been described mainly in phagocytic cells (1) , was recently shown to exist in nonphagocytic cells (1, 31) . However, the mode of activation of this oxidase in these cells is not known well. In 3T3-L1 adipocytes, it has been shown that ROS production was largely sensitive to the flavoprotein inhibitor DPI, a potential NADPH oxidase inhibitor (31) . We report that DPI significantly decreased ROS in HF dipocytes. On the other hand, inhibitors for xanthine oxidase and NOS, and for AGE formation, or the mitochondrial uncoupler FCCP, had no effect on ROS, further suggesting that the major source for enhanced ROS production is NADPH oxidase. Our studies also suggest that PKC-␦ is an important regulator of ROS in HF adipocytes. Rottlerin, a selective PKC-␦ inhibitor, suppressed ROS levels, and adenoviral-mediated expression of PKC-␦ protein affected ROS: expression of the dominant negative mutant PKC-␦ reduced ROS levels by 30%, and overexpression of the wild-type PKC-␦ enhanced ROS levels twofold (Fig. 3D) . It is noteworthy that PKC-␦ has been previously implicated in NADPH oxidase activation in various cells (2) and has been shown to be recruited to the complex assembly formation of the enzyme's components (6) . The mechanisms by which PKC-␦ activates NADPH oxidase are not fully clear. It may be that PKC-␦ phosphorylates the cytoplasmic subunits of the oxidase, such as p47
phox , and initiates its translocation of the membrane (15, 38) . Future studies should further address this problem.
PKC-␦ regulates intracellular ROS production in normal adipocytes, which indicates that its role is not unique to HF adipocytes. Rather, abnormal regulation of PKC-␦ in HF adipocytes leads to sustained/enhanced activation of ROS production. These differences are crucial for the well-being of the cell. Although PKC-␦ and ROS are tightly regulated in normal adipocytes, their activity levels are increased in HF adipocytes, provoking/enhancing intracellular pathways, which leads to the detrimental effects associated with oxidative stress (3, 13, 14, 29) .
How is PKC-␦ activated in HF adipocytes? Our studies suggest two alternative routes that can activate PKC-␦, glucose, and oxidative stress. Hyperglycemia is a known factor Fig. 5 . Model for role of PKC-␦ in ROS production in HF adipocytes. Glucose influx into HF adipocytes is largely increased due to upregulation of GLUT1 (45) . High glucose influx activates PKC-␦, which in turn enhances ROS generation via activation of NADPH oxidase. Elevation in ROS may feedback loop into activation of PKC-␦. This vicious cycle further amplifies oxidative stress in HF adipocytes. Inhibition of PKC-␦ suppresses ROS production and may represent a way by which oxidative stress is reduced and its deleterious effects are attenuated in diabetic adipocytes. Fig. 4 . Effect of glucose on ROS and PKC-␦ activity in HF adipocytes. A: HF adipocytes were incubated with indicated concentrations of glucose for 2.5 h. ROS levels were determined as explained in MATERIALS AND METHODS. Results represent means Ϯ SE of 2 independent experiments, presented as fold inhibition of ROS levels determined in HF adipocytes incubated with 5 mM glucose. B: HF adipocytes were incubated with indicated concentrations of glucose for 2.5 h. PKC-␦ activity was assayed in immunoprecipitate complexes, as described in MATERIALS AND METHODS. Shown is phosphorylation of PKC-␦ substrate histone H1 (top), and expression of PKC-␦ was determined by Western blot analysis with PKC-␦ antibody (bottom). C: fat tissues were infected with ␤-Gal or DN-PKC-␦ adenoviruses, as described in MATERIALS AND METHODS. Adipocytes were isolated and incubated with indicated concentrations of glucose for 2.5 h. ROS levels were determined as explained in MATERIALS AND METHODS. Results represent means Ϯ SE of 2 independent experiments, presented as fold inhibition of ROS levels determined in ␤-Gal (control)-expressing cells.
activating PKCs, and it has been shown by numerous studies that, in cells chronically exposed to high glucose or in hypergluycemic animals, PKC is activated (20, 27, 29, 48) . The fact that glucose suppressed PKC-␦ (Fig. 4B) suggested that high glucose influx into HF adipocytes (45) activates PKC-␦. This, in turn, promotes the activation of NADPH oxidase. It is noteworthy that similar observations were recently reported in vascular cells, showing that high glucose activated NADPH oxidase in a PKC-dependent fashion, although the specific PKC isoform has not been determined (19, 20) . An additional route for activation of PKC-␦ is oxidative stress. This has been initially shown in H 2 O 2 -treated COS-7 cells (25) and vascular muscle cells (41) . In HF adipocytes, we previously showed that oxidative stress activates PKC-␦ (45) . Thus it appears that a vicious cycle operates between ROS and PKC-␦. Once activated by glucose, PKC-␦ enhances ROS production, which, in turn, feedback loops into the activation of PKC-␦ (Fig. 5) . These consequential events amplify oxidative stress and may be attenuated by glucose depletion or inhibition of PKC-␦.
In summary, we propose a new role for PKC-␦ in the activation of oxidative stress in HF adipocytes and suggest that its inhibition may be a way to prevent the deleterious effects of oxidative stress that develop in the diabetic fat tissue.
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